

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

FRENKEN ET AL

Serial No. 09/807,172

Group Art Unit: Unknown

Filed: April 10, 2001

Examiner: Unknown

For: ANTIGEN-BINDING PROTEINS

January 31, 2002

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, D.C. 20231


Sir:

Herewith are copies of references for the Examiner's consideration in the examination of this application. These references were listed on PTO-1449 submitted with the filing of the above application on April 10, 2001. A copy of the PTO-1449 is attached for the Examiner's convenience.

The Examiner is requested to consider the attachments in the examination of this application.

Respectfully submitted,

MORGAN LEWIS & BOCKIUS, LLP

By 

Paul N. Kokulis
Reg. No. 16773

PNK:mh
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Phone: (202) 739-5455

MORGAN LEWIS & BOCKIUS LLP

PLEASE STAMP AND RETURN TO SHOW RECEIPT OF:

First Inventor:	FRENKEN ET AL	Atty:	Paul N. Kokulis
U.S. Serial No.:	09/807,172	Date:	January 31, 2002
Client/Matter No.:	056159/0001		
Due Date:	January 31, 2002		

1. INFORMATION DISCLOSURE STATEMENT
2. PTO-1449 with References
3. *Change of Correspondence Address*

PNK/mah



17

2/1/02

Atty.
Dkt. No.

Inv#

Client Ref.

279470

T 3077 (V)

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Applicant: FRENKEN, Léo G. J. et al

Appln. No.: 09/807,172

Filing Date: April 10, 2001

Examiner:

Group Art Unit:

Date: April 10, 2001

Page

1

of

1

U.S. PATENT DOCUMENT

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
ER						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
	FR	WO 93/02198	02/1993	WIPO				
	GR	WO 94/13804	06/1994	WIPO				
	HR	WO 97/14719	04/1997	WIPO				
	IR							
	JR							
	KR							

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

LR	H. HOOGENBOOM: "Mix and march: Building manifold binding sites." NATURE BIOTECHNOLOGY, vol. 15, no. 2, February 1997, pages 125-126, XP002110046 New York, NY, USA, page 126, right-hand column, line 30-line 39, figure 1			
MR	M.SRISODSUK ET AL.: "Role of the interdomain linker peptide of Trichoderma reesei cellobiohydrolase I in its interaction with crystalline cellulose." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 28, 5 October 1993, pages 20756-20761, XP002112074 Baltimore, MD, USA, abstract, figure 1			
NR	P. HOLLIGER ET AL.: "Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody," PROTEIN ENGINEERING, vol. 9, no. 3, March 1996, pages 299-305, XP002112075 Oxford, GB, abstract, figure 1			
OR	A. PLUCKTHUN ET AL.: "New protein engineering approaches to multivalent and bispecific antibody fragments." IMMUNOTECHNOLOGY, vol. 3, no. 2, June 1997, pages 83-105, XP004088466 Amsterdam, NL, page 98, right-hand column, line 27 - line 46, figure 6E			
PR	P. PORTOGHESE ET AL.: "Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers." JOURNAL OF MEDICINAL CHEMISTRY, vol. 29, no. 9, September 1986, pages 1650-1653, XP002112076 Washington, DC USA, abstract, figure 2			
QR	K. ALFTHAN ET AL.: "Properties of a single-chain antibody containing different linker peptides." PROTEIN ENGINEERING, vol. 8, no. 7, July 1995, pages 725-731, XP002112077, Oxford, GB, abstract, figure 1A			

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.